Skip to main content
Erschienen in: Pediatric Nephrology 6/2021

17.11.2020 | Original Article

Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage

verfasst von: Mariana Luna, Mariana Kamariski, Iliana Principi, Victoria Bocanegra, Patricia G. Vallés

Erschienen in: Pediatric Nephrology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is the main cause of pediatric acute kidney injury (AKI) in Argentina. Endothelial injury is the trigger event in the microangiopathic process. The host inflammatory response to toxin and E. coli lipopolysaccharide (LPS) is involved in disease pathophysiology.

Methods

This retrospective study describes pediatric STEC-HUS patients with multiorgan involvement at the initial phase of disease. A retrospective study of critically ill HUS patients with evidence of E. coli infection was conducted through a period of 15 years.

Results

Forty-four patients 35.4 ± 4.1 months were admitted to the intensive care unit for 21 ± 2 days. Mechanical ventilation was required in 41 patients, early inotropic support in 37, and 28 developed septic shock. Forty-one patients required kidney replacement therapy for 12 ± 1 days. Forty-one patients showed neurological dysfunction. Dilated cardiomyopathy was demonstrated in 3 patients, left ventricular systolic dysfunction in 4, and hypertension in 17. Four patients had pulmonary hemorrhage, and acute respiratory distress syndrome in 2. Colectomy for transmural colonic necrosis was performed in 3 patients. Thirty-seven patients were treated with therapeutic plasma exchange, and 28 patients received methylprednisolone (10 mg/kg for 3 days). Of the surviving 32 patients, neurological sequelae were seen in 11 and chronic kidney failure in 5.

Conclusions

Severe clinical outcome at onset suggests an amplified inflammatory response after exposure to Shiga toxin and/or E. coli LPS. STEC-HUS associated with severe neurological involvement, hemodynamic instability, and AKI requires intensive care and focused therapy.
Literatur
1.
Zurück zum Zitat Oualha M, Pierrepont S, Krug P, Gitiaux C, Hubert P, Lesage F, Salomon R (2018) Postdiarrheal hemolytic and uremic syndrome with severe multiorgan involvement and associated early risk factors. Arch Pediatr 25:118–125PubMedCrossRef Oualha M, Pierrepont S, Krug P, Gitiaux C, Hubert P, Lesage F, Salomon R (2018) Postdiarrheal hemolytic and uremic syndrome with severe multiorgan involvement and associated early risk factors. Arch Pediatr 25:118–125PubMedCrossRef
2.
Zurück zum Zitat Gianantonio C, Vitaco M, Mendilaharzu F, Rutty A, Mendilaharzu J (1964) The hemolytic uremic syndrome. J Pediatr 54:478–491CrossRef Gianantonio C, Vitaco M, Mendilaharzu F, Rutty A, Mendilaharzu J (1964) The hemolytic uremic syndrome. J Pediatr 54:478–491CrossRef
4.
Zurück zum Zitat Rivas M, Sosa-Estani S, Rangel J, Caletti MG, Vallés P, Roldán CD, Balbi L, Marsano de Mollar MC, Amoedo D, Miliwebsky E, Chinen I, Hoekstra RM, Mead P, Griffin PM (2008) Risk Factors for sporadic shiga toxin–producing Escherichia coli infections in children, Argentina). Emerg Infect Dis 14:763–771PubMedPubMedCentralCrossRef Rivas M, Sosa-Estani S, Rangel J, Caletti MG, Vallés P, Roldán CD, Balbi L, Marsano de Mollar MC, Amoedo D, Miliwebsky E, Chinen I, Hoekstra RM, Mead P, Griffin PM (2008) Risk Factors for sporadic shiga toxin–producing Escherichia coli infections in children, Argentina). Emerg Infect Dis 14:763–771PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Karmali MA, Steele BT, Petric M, Lim C (1983) Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1:619–620PubMedCrossRef Karmali MA, Steele BT, Petric M, Lim C (1983) Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1:619–620PubMedCrossRef
6.
Zurück zum Zitat Rivas M, Miliwebsky E, Chinen I, Roldán CD, Balbi L, García B, Fiorilli G, Sosa-Estani S, Kincaid J, Rangel J, Griffin PM, Case-Control Study Group (2006) Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog Dis 3:88–96PubMedCrossRef Rivas M, Miliwebsky E, Chinen I, Roldán CD, Balbi L, García B, Fiorilli G, Sosa-Estani S, Kincaid J, Rangel J, Griffin PM, Case-Control Study Group (2006) Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog Dis 3:88–96PubMedCrossRef
7.
Zurück zum Zitat Tarr GAM, Stokowski T, Shringi S, Tarr PI, Freedman S, Oltean HN, Rabinowitz PM, Chui L (2019) Contribution and interaction of Shiga toxin genes to Escherichia coli O157:H7 virulence. Toxins 11:607PubMedCentralCrossRef Tarr GAM, Stokowski T, Shringi S, Tarr PI, Freedman S, Oltean HN, Rabinowitz PM, Chui L (2019) Contribution and interaction of Shiga toxin genes to Escherichia coli O157:H7 virulence. Toxins 11:607PubMedCentralCrossRef
8.
Zurück zum Zitat Pianciola L, D’Astek BA, Mazzeo M, Chinen I, Masana M, Rivas M (2016) Genetic features of human and bovine Escherichia coli O157:H7 strains isolated in Argentina. Int J Med Microbiol 306:123–130PubMedCrossRef Pianciola L, D’Astek BA, Mazzeo M, Chinen I, Masana M, Rivas M (2016) Genetic features of human and bovine Escherichia coli O157:H7 strains isolated in Argentina. Int J Med Microbiol 306:123–130PubMedCrossRef
9.
Zurück zum Zitat Schüller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD (2007) Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect 9:35–39PubMedCrossRef Schüller S, Heuschkel R, Torrente F, Kaper JB, Phillips AD (2007) Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect 9:35–39PubMedCrossRef
10.
Zurück zum Zitat Schüller S (2011) Shiga toxin interaction with human intestinal epithelium. Toxins 3:3626–3639CrossRef Schüller S (2011) Shiga toxin interaction with human intestinal epithelium. Toxins 3:3626–3639CrossRef
11.
Zurück zum Zitat Zoja C, Buelli S, Morigi M (2019) Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 34:379–388PubMedCrossRef Zoja C, Buelli S, Morigi M (2019) Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 34:379–388PubMedCrossRef
12.
Zurück zum Zitat Vallés PG, Melechuck S, González A, Manucha W, Bocanegra V, Vallés R (2012) Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome. Pediatr Nephrol 27:407–415PubMedCrossRef Vallés PG, Melechuck S, González A, Manucha W, Bocanegra V, Vallés R (2012) Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome. Pediatr Nephrol 27:407–415PubMedCrossRef
13.
Zurück zum Zitat Exeni R, Fernandez-Brando R, Santiago A, Fiorentino G, Exeni A, Ramos M, Palermo M (2018) Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 33:2057–2071PubMedCrossRef Exeni R, Fernandez-Brando R, Santiago A, Fiorentino G, Exeni A, Ramos M, Palermo M (2018) Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 33:2057–2071PubMedCrossRef
14.
Zurück zum Zitat Shimizu M (2020) Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS. Pediatr Int 62:308–315PubMedCrossRef Shimizu M (2020) Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS. Pediatr Int 62:308–315PubMedCrossRef
15.
Zurück zum Zitat Magnus T, Röther J, Simova O, Meier-Cillien M, Repenthin J, Möller F, Gbadamosi J, Panzer U, Wengenroth M, Hagel C, Kluge S, Stahl R, Wegscheider K, Urban P, Eckert B, Glatzel M, Jens Fiehler J, Gerloff C (2012) The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 135:1850–1859CrossRefPubMed Magnus T, Röther J, Simova O, Meier-Cillien M, Repenthin J, Möller F, Gbadamosi J, Panzer U, Wengenroth M, Hagel C, Kluge S, Stahl R, Wegscheider K, Urban P, Eckert B, Glatzel M, Jens Fiehler J, Gerloff C (2012) The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 135:1850–1859CrossRefPubMed
16.
Zurück zum Zitat Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P (2015) Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathol Biol (Paris) 63:136–143CrossRef Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P (2015) Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathol Biol (Paris) 63:136–143CrossRef
17.
Zurück zum Zitat Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181PubMedCrossRef Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181PubMedCrossRef
18.
Zurück zum Zitat Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561–2563PubMedCrossRef Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561–2563PubMedCrossRef
19.
Zurück zum Zitat Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204PubMedPubMedCentralCrossRef Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Vallés PG, Pesle S, Piovano L, Davila E, Peralta M, Principi I, Lo Giudice P (2005) Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome similar to septic shock. Medicina (B Aires) 65:395–401 Vallés PG, Pesle S, Piovano L, Davila E, Peralta M, Principi I, Lo Giudice P (2005) Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome similar to septic shock. Medicina (B Aires) 65:395–401
21.
Zurück zum Zitat Braune SA, Wichmann D, von Heinz MC, Nierhaus A, Becker H, Meyer TN, Meyer GP, Müller-Schulz M, Fricke J, de Weerth A, Hoepker WW, Fiehler J, Magnus T, Gerloff C, Panzer U, Stahl RAK, Wegscheider K, Kluge S (2013) Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 41:1702–1710PubMedCrossRef Braune SA, Wichmann D, von Heinz MC, Nierhaus A, Becker H, Meyer TN, Meyer GP, Müller-Schulz M, Fricke J, de Weerth A, Hoepker WW, Fiehler J, Magnus T, Gerloff C, Panzer U, Stahl RAK, Wegscheider K, Kluge S (2013) Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 41:1702–1710PubMedCrossRef
23.
Zurück zum Zitat Beers SR, Wisniewski SR, Garcia-Filion P, Tian Y, Hahner T, Berger RP, Bell M, Adelson PD (2012) Validity of a pediatric version of the Glasgow outcome scale-extended. J Neurotrauma 29:1126–1139PubMedPubMedCentralCrossRef Beers SR, Wisniewski SR, Garcia-Filion P, Tian Y, Hahner T, Berger RP, Bell M, Adelson PD (2012) Validity of a pediatric version of the Glasgow outcome scale-extended. J Neurotrauma 29:1126–1139PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Karmali MA, Gannon V, Sargeant JM (2010) Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 140:360–370PubMedCrossRef Karmali MA, Gannon V, Sargeant JM (2010) Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 140:360–370PubMedCrossRef
25.
Zurück zum Zitat Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390:681–696PubMedCrossRef Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390:681–696PubMedCrossRef
26.
Zurück zum Zitat Rivas M, Chinen I, Miliwebsky E, Masana M (2014) Risk factors for Shiga toxin-producing Escherichia coli-associated human diseases. Microbiol Spectr 2:1–14CrossRef Rivas M, Chinen I, Miliwebsky E, Masana M (2014) Risk factors for Shiga toxin-producing Escherichia coli-associated human diseases. Microbiol Spectr 2:1–14CrossRef
27.
Zurück zum Zitat Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, Deleré Y, an der Heiden M, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber M, Frank C, Fricke G, Greiner M, Höhle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner B, Stark K, Kühne M (2011) German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 365:1763–1770PubMedCrossRef Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, Deleré Y, an der Heiden M, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber M, Frank C, Fricke G, Greiner M, Höhle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner B, Stark K, Kühne M (2011) German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 365:1763–1770PubMedCrossRef
28.
Zurück zum Zitat Torres AG, Amaral MM, Bentancor L, Galli L, Goldstein J, Krüger A, Rojas-Lopez M (2018) Recent advances in Shiga toxin-producing Escherichia coli research in Latin America. Microorganisms 6:100PubMedCentralCrossRef Torres AG, Amaral MM, Bentancor L, Galli L, Goldstein J, Krüger A, Rojas-Lopez M (2018) Recent advances in Shiga toxin-producing Escherichia coli research in Latin America. Microorganisms 6:100PubMedCentralCrossRef
29.
Zurück zum Zitat Scheutz F (2014) Taxonomy meets public health: the case of Shiga toxin-producing Escherichia coli. Microbiol Spectr 2:EHEC-0019–2013CrossRef Scheutz F (2014) Taxonomy meets public health: the case of Shiga toxin-producing Escherichia coli. Microbiol Spectr 2:EHEC-0019–2013CrossRef
30.
Zurück zum Zitat Joseph A, Cointe A, Kurkdjian PM, Rafat C, Hertig A (2020) Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins (Basel) 12:67CrossRef Joseph A, Cointe A, Kurkdjian PM, Rafat C, Hertig A (2020) Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins (Basel) 12:67CrossRef
31.
Zurück zum Zitat Khalid M, Andreoli S (2019) Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 34:2495–2507PubMedCrossRef Khalid M, Andreoli S (2019) Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 34:2495–2507PubMedCrossRef
32.
Zurück zum Zitat Anjay MA, Anoop P, Britland A (2007) Leukocytosis as a predictor for progression to haemolytic uraemic syndrome in Escherichia coli O157:H7 infection. Arch Dis Child 92:820–823PubMedCrossRef Anjay MA, Anoop P, Britland A (2007) Leukocytosis as a predictor for progression to haemolytic uraemic syndrome in Escherichia coli O157:H7 infection. Arch Dis Child 92:820–823PubMedCrossRef
33.
Zurück zum Zitat Buteau C, Proulx F, Chaibou M, Raymond D, Clermont MJ, Mariscalco MM, Lebel MH, Seidman E (2000) Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J 19:642–647PubMedCrossRef Buteau C, Proulx F, Chaibou M, Raymond D, Clermont MJ, Mariscalco MM, Lebel MH, Seidman E (2000) Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J 19:642–647PubMedCrossRef
34.
Zurück zum Zitat Alconcher L, Coccia P, Suarez A, Monteverde M, Perez M (2018) Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol 33:1791–1798PubMedCrossRef Alconcher L, Coccia P, Suarez A, Monteverde M, Perez M (2018) Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol 33:1791–1798PubMedCrossRef
35.
Zurück zum Zitat Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A (2016) Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. BMC Infect Dis 16:285PubMedPubMedCentralCrossRef Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A (2016) Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. BMC Infect Dis 16:285PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Piètrement C, Champion G, Ulinski T, Deschênes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218–1228PubMedPubMedCentralCrossRef Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Piètrement C, Champion G, Ulinski T, Deschênes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5:1218–1228PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Eisenhauer PB, Jacewicz MS, Conn KJ, Koul O, Wells JM, Fine RE (2004) Escherichia coli Shiga toxin 1 and TNF-alfa induce cytokine release by human cerebral micro- vascular endothelial cells. Microb Pathog 36:189–196PubMedCrossRef Eisenhauer PB, Jacewicz MS, Conn KJ, Koul O, Wells JM, Fine RE (2004) Escherichia coli Shiga toxin 1 and TNF-alfa induce cytokine release by human cerebral micro- vascular endothelial cells. Microb Pathog 36:189–196PubMedCrossRef
39.
Zurück zum Zitat Takahashi K, Funata N, Ikuta F, Sato S (2008) Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. Neuroinflammation 21:5–11 Takahashi K, Funata N, Ikuta F, Sato S (2008) Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. Neuroinflammation 21:5–11
40.
Zurück zum Zitat Arvidsson I, Ståhl AL, Hedström MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D (2015) Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194:2309–2318PubMedCrossRef Arvidsson I, Ståhl AL, Hedström MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D (2015) Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194:2309–2318PubMedCrossRef
41.
Zurück zum Zitat Ståhl A, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503–5513PubMedCrossRef Ståhl A, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503–5513PubMedCrossRef
42.
Zurück zum Zitat Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394–6400PubMedCrossRef Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394–6400PubMedCrossRef
43.
Zurück zum Zitat Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H, German-Austrian HUS Study Group (2012) Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late emerging sequelae. Clin Infect Dis 54:1413–1421PubMedCrossRef Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H, German-Austrian HUS Study Group (2012) Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late emerging sequelae. Clin Infect Dis 54:1413–1421PubMedCrossRef
44.
Zurück zum Zitat Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR (1997) Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 11:156–160PubMedCrossRef Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR (1997) Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 11:156–160PubMedCrossRef
45.
Zurück zum Zitat Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J (2018) Short- and long-term renal outcome of hemolytic-uremic syndrome in childhood. Front Pediatr 6:220PubMedPubMedCentralCrossRef Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J (2018) Short- and long-term renal outcome of hemolytic-uremic syndrome in childhood. Front Pediatr 6:220PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Rigamonti D, Simonetti GD (2016) Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr 175:1927–1931PubMedCrossRef Rigamonti D, Simonetti GD (2016) Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr 175:1927–1931PubMedCrossRef
47.
Zurück zum Zitat Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED (1994) Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 125:519–526PubMedCrossRef Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED (1994) Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 125:519–526PubMedCrossRef
48.
Zurück zum Zitat Gallo EG, Gianantonio CA (1995) Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol 9:117–119PubMedCrossRef Gallo EG, Gianantonio CA (1995) Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol 9:117–119PubMedCrossRef
49.
Zurück zum Zitat Keir LS, Marks SD, Kim JJ (2012) Shiga toxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 6:195–208PubMedPubMedCentral Keir LS, Marks SD, Kim JJ (2012) Shiga toxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 6:195–208PubMedPubMedCentral
50.
Zurück zum Zitat Walsh PR, Johnson S (2018) Treatment and management of children with haemolytic uraemic sindrome. Arch Dis Child 103:285–291PubMedCrossRef Walsh PR, Johnson S (2018) Treatment and management of children with haemolytic uraemic sindrome. Arch Dis Child 103:285–291PubMedCrossRef
51.
Zurück zum Zitat Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau MC, Schild R, Lemke J, Beringer O, Müller D, Härtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper MJ (2017) Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4. Clin Infect Dis 64:1637–1643PubMedCrossRef Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau MC, Schild R, Lemke J, Beringer O, Müller D, Härtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper MJ (2017) Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4. Clin Infect Dis 64:1637–1643PubMedCrossRef
52.
Zurück zum Zitat The German EHEC-HUS Registry (2011) The German 2011 epidemic of Escherichia coli O157:H7 infections: association with intravenous Shiga toxin-producing E. coli—the nephrological view. Nephrol Dial Transplant 26:2723–2726CrossRef The German EHEC-HUS Registry (2011) The German 2011 epidemic of Escherichia coli O157:H7 infections: association with intravenous Shiga toxin-producing E. coli—the nephrological view. Nephrol Dial Transplant 26:2723–2726CrossRef
53.
Zurück zum Zitat Garg AX, Suri RS, Barrowman N, Rehman N, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic suremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370PubMedCrossRef Garg AX, Suri RS, Barrowman N, Rehman N, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic suremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290:1360–1370PubMedCrossRef
54.
Zurück zum Zitat Keenswijk W, Raes A, De Clerck M, Vande Walle J (2019) Is plasma exchange efficacious in Shiga toxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Ther Apher Dial 23:118–125PubMedCrossRef Keenswijk W, Raes A, De Clerck M, Vande Walle J (2019) Is plasma exchange efficacious in Shiga toxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Ther Apher Dial 23:118–125PubMedCrossRef
55.
Zurück zum Zitat Colic E, Dieperink H, Titlestad K, Tepel M (2011) Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 378:1089–1093PubMedCrossRef Colic E, Dieperink H, Titlestad K, Tepel M (2011) Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 378:1089–1093PubMedCrossRef
56.
Zurück zum Zitat Ruggenenti P, Remuzzi G (2011) A German out-break of haemolytic uraemic syndrome. Lancet 378:1057–1058PubMedCrossRef Ruggenenti P, Remuzzi G (2011) A German out-break of haemolytic uraemic syndrome. Lancet 378:1057–1058PubMedCrossRef
57.
Zurück zum Zitat Mor M, Ashkenazi S (2014) The dilemma of antimicrobia ltreatment of Shiga toxin-producing Escherichia coli. Pediatr Infect Dis J 33:979–981PubMedCrossRef Mor M, Ashkenazi S (2014) The dilemma of antimicrobia ltreatment of Shiga toxin-producing Escherichia coli. Pediatr Infect Dis J 33:979–981PubMedCrossRef
58.
Zurück zum Zitat Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhöner P, Büning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin–producing Enteroaggregative Escherichia coli O104:H4. JAMA 307:1046–1052PubMedCrossRef Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhöner P, Büning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin–producing Enteroaggregative Escherichia coli O104:H4. JAMA 307:1046–1052PubMedCrossRef
59.
Zurück zum Zitat Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565PubMedPubMedCentralCrossRef Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR (2012) Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 55:33–41PubMedPubMedCentralCrossRef Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR (2012) Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 55:33–41PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P (1998) Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 12:101–104PubMedCrossRef Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P (1998) Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 12:101–104PubMedCrossRef
62.
Zurück zum Zitat Yahiro K, Nagasawa S, Ichimura K, Takeuchi H, Ogura K, Tsutsuki H, Shimizu T (2018) Mechanism of inhibition of Shiga-toxigenic Escherichia coli SubAB cytotoxicity by steroids and diacylglycerol analogues. Cell Death Dis 4:22CrossRef Yahiro K, Nagasawa S, Ichimura K, Takeuchi H, Ogura K, Tsutsuki H, Shimizu T (2018) Mechanism of inhibition of Shiga-toxigenic Escherichia coli SubAB cytotoxicity by steroids and diacylglycerol analogues. Cell Death Dis 4:22CrossRef
63.
Zurück zum Zitat Pinto A, Berdasco C, Arenas-Mosquera D, Cangelosi A, Geoghegan PA, Nuñez MC, Goldstein J (2018) Anti-inflammatory agents reduce microglial response, demyelinating process and neuronal toxin uptake in a model of encephalopathy produced by Shiga toxin 2. Int J Med Microbiol 308:1036–1042PubMedCrossRef Pinto A, Berdasco C, Arenas-Mosquera D, Cangelosi A, Geoghegan PA, Nuñez MC, Goldstein J (2018) Anti-inflammatory agents reduce microglial response, demyelinating process and neuronal toxin uptake in a model of encephalopathy produced by Shiga toxin 2. Int J Med Microbiol 308:1036–1042PubMedCrossRef
64.
Zurück zum Zitat Shenker Y, Skatrud JB (2001) Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 163:1520–1523PubMedCrossRef Shenker Y, Skatrud JB (2001) Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med 163:1520–1523PubMedCrossRef
65.
Zurück zum Zitat Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439PubMedCrossRef Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439PubMedCrossRef
66.
Zurück zum Zitat Buelli S, Zoja C, Remuzzi G, Morigi M (2019) Complement activation contributes to the pathophysiology of Shiga toxin-associated hemolytic uremic syndrome. Microorganisms 7:15PubMedCentralCrossRef Buelli S, Zoja C, Remuzzi G, Morigi M (2019) Complement activation contributes to the pathophysiology of Shiga toxin-associated hemolytic uremic syndrome. Microorganisms 7:15PubMedCentralCrossRef
67.
Zurück zum Zitat Percheron L, Gramada R, Tellier S, Salomon R, Harambat J (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33:1385–1394PubMedCrossRef Percheron L, Gramada R, Tellier S, Salomon R, Harambat J (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33:1385–1394PubMedCrossRef
Metadaten
Titel
Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage
verfasst von
Mariana Luna
Mariana Kamariski
Iliana Principi
Victoria Bocanegra
Patricia G. Vallés
Publikationsdatum
17.11.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 6/2021
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-020-04829-4

Weitere Artikel der Ausgabe 6/2021

Pediatric Nephrology 6/2021 Zur Ausgabe

Letter to the Editors

Response to Majeranowski

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Durch übermäßige Internetnutzung wird oft die Schule verpasst

Häufige Fehlzeiten in der Schule können durch physische und psychische Probleme verursacht werden. Wie in einer Studie aus Finnland nun belegt wird, führt auch die exzessive Nutzung des Internets gehäuft zu Abwesenheiten.

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.